Can We Synthesize Ibogaine? What Chemists Say

Ibogaine is a complex indole alkaloid naturally occurring in the root bark of the Tabernanthe iboga shrub, native to West Central Africa. This natural product is commonly identified as 12-methoxyibogamine and has the formula C20H26N2O. Its unusual polycyclic skeleton and multiple chiral centers explain why chemists describe it as a challenging molecule.

The natural source is not merely a supply issue. Traditional use of Tabernanthe iboga by indigenous communities dates back centuries in spiritual, healing, and initiation contexts, and the plant is considered sacred in Bwiti spiritual practice in Gabon and Cameroon. A general account of the plant’s cultural and botanical setting is available through the botanical record for Tabernanthe iboga.

Extraction from iboga root bark can make a plant-derived compound available, but wild harvesting raises sustainability and ethical considerations. Scarcity, destructive collection, and an uncertain supply chain strengthen the case for a sustainable source that does not depend entirely on a medicinal plant from the plant kingdom.

Early attempts at ibogaine total synthesis

The first total synthesis of ibogaine was achieved in 1966 by the team led by G. Büchi at MIT. The Büchi synthesis marked a major natural product milestone: it showed that synthetic chemists could reach a molecule once available only through its natural source.

The Büchi synthesis used a multi-step sequence beginning with indole derivatives. It was valuable proof of concept, not a blueprint for scalable production. Low overall yield, extensive operations, and difficult stereocontrol made the approach impractical for large manufacturing processes.

Early synthetic routes often struggled to construct the ibogamine core without generating mixtures of stereoisomers. Ernest Wenkert and James P. Kutney also contributed to the early exploration of these chemical pathways. Historical work matters because it framed the central problem: not whether an indole alkaloid can be made, but whether it can be made selectively, efficiently, and consistently.

A recent scholarly overview of the field is collected in this open-access discussion of ibogaine’s translational challenges, which places the compound’s chemistry beside questions of pharmacology and cardiac risk.

Convergent synthesis and semisynthesis

Convergent synthesis offers a pathway to ibogaine by preparing complex pieces separately and joining them strategically. This can reduce the longest linear sequence and improve reaction efficiency. A 2025 report described a modular, gram-scale, seven-step synthesis of racemic ibogaine, a result highlighted by UC Davis researchers’ account of the total synthesis achievement.

The same development was described for chemistry audiences in Chemistry World’s report on the seven-step route. Such work does not mean every manufacturing hurdle has disappeared. It does show that shorter, modular chemical synthesis can make experimental access more realistic.

Semisynthesis remains another active option. Rather than beginning from simple feedstocks, semisynthesis starts with more available natural precursors or related alkaloids, then transforms them into ibogaine or useful analogs. That bridge between extraction and total synthesis may be attractive when a precursor is more abundant than iboga root bark.

Technical discussion is continuing in the scientific community, including the posted record of efficient modular synthesis work and a public chemistry conversation about researchers’ total-synthesis result.